Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2026-06 · 46 (6)
DOI: 10.1002/phar.70150 ↗Kurz gefasst
Fallbericht in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 11.05.2026. Verfasst von Jana Stojanova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, Australia. Hauptthemen laut MEDLINE: Sirolimus, Ketamine, Tacrolimus, Immunosuppressive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Drug interactions involving immunosuppressants can compromise transplant outcomes. Although repeated ketamine administration induces hepatic enzymes in experimental models, clinical reports of induced clearance of cytochrome P450 (CYP) substrates are lacking. Continuous subcutaneous ketamine infusions are increasingly used for acute pain management. We present a case of difficult‐to‐maintain tacrolimus and sirolimus concentrations in the context of subcutaneous ketamine infusion for acute pain management.
Methods
A 55‐year‐old male heart transplant recipient received continuous subcutaneous ketamine (5.2–10.4 mg/h) for pain management following lower limb thrombectomy. Tacrolimus and sirolimus concentrations were monitored throughout hospitalization and rehabilitation. Population pharmacokinetic modeling with Bayesian estimation characterized temporal clearance changes, incorporating inter‐occasion variability across six periods (pre‐, during‐, and weekly post‐ketamine administration for 4 weeks).
Results
Following ketamine initiation, tacrolimus and sirolimus concentrations remained subtherapeutic despite dose escalations of 1.8‐fold and 5‐fold, respectively. Pharmacokinetic modeling revealed approximately 2‐fold clearance increases during ketamine administration, peaking 1 week after initiation. Following ketamine discontinuation, tacrolimus and sirolimus concentrations progressively increased over 3 weeks, consistent with enzyme induction and recovery. Drug Interaction Probability Scale assessment indicated probable interaction (score + 5). Brief concomitant flucloxacillin use may have contributed to the observed changes.
Conclusions
This case provides preliminary evidence of potential interaction between ketamine and CYP3A4‐metabolized immunosuppressants. Clinicians should consider increased therapeutic drug monitoring when using ketamine with narrow therapeutic range medications, continuing approximately 3 weeks post‐discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, Australia.
- School of Clinical Medicine, St Vincent's Healthcare Clinical Campus, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia.
- Pharmacy Department, St. Vincent's Hospital, Sydney, Australia.
- Division of Translational and Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
- Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
- Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
ORCID-Profile: Jana Stojanova, Bridin Murnion, Tomoyuki Mizuno, Nuala Helsby, Kavitha Muthiah, Richard Day
Zitieren
APA
Stojanova, J., Murnion, B., Burrows, F., Carlos, L., Mizuno, T., Nadai, T., Irie, K., Helsby, N., Muthiah, K., & Day, R. (2026). Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 46(6). https://doi.org/10.1002/phar.70150
Vancouver
Stojanova J, Murnion B, Burrows F, Carlos L, Mizuno T, Nadai T, et al. Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2026;46(6). doi:10.1002/phar.70150
BibTeX
@article{Stojanova2026,
author = {Stojanova, Jana and Murnion, Bridin and Burrows, Fay and Carlos, Lilibeth and Mizuno, Tomoyuki and Nadai, Takanobu and Irie, Kei and Helsby, Nuala and Muthiah, Kavitha and Day, Richard},
title = {Continuous Subcutaneous Ketamine Infusion May Induce Tacrolimus and Sirolimus Clearance: A Case Report},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2026},
volume = {46},
number = {6},
doi = {10.1002/phar.70150}
}
EUVIMED